CYDY CytoDyn

CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on September 30, 2020

CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on September 30, 2020

VANCOUVER, Washington, Sept. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reminds investors today the 2020 Virtual Annual Meeting of Stockholders will be held at 9:30 am PT on September 30, 2020. As stated in the Company’s proxy statement dated September 1, 2020, due to public health concerns relating to the coronavirus pandemic, stockholders will not be able to attend the Annual Meeting in person. The Company provides the following information as a reminder on how stockholders and guests can participate in the virtual meeting format:

Time: 9:30 am PT

Webcast login:

Stockholder questions: Submitted online via the meeting link, passcode CYDY2020 and their individual control number noted on their proxy card. Guests will not be able to submit questions during the meeting.

At the conclusion of the business portion of the meeting, Nader Pourhassan, Ph.D., President and Chief Executive Officer, will present an overview of the Company via a slide deck, which will be available on the Company’s website () at 9:30 am PT. In light of the limited amount of time for the meeting, stockholders are also encouraged to submit questions to management before 8:00 am PT tomorrow to: .

CYTODYN CONTACTS

Investors:

Michael Mulholland

Office: 360.980.8524, ext. 102

EN
29/09/2020

Underlying

CYDYCytoDyn

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Present at the LD Micro Main Event XIX Investor Conference

CytoDyn to Present at the LD Micro Main Event XIX Investor Conference CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), announced that CFO Robert E. Hoffman will present a corporate...

October 9, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

September 2025 Letter to Shareholders

September 2025 Letter to Shareholders VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to share the progress we have made in advancing leronlimab as an innovative treatment in oncology. We remain confident that addressing critical unmet needs in this field is the best way to build value while improving the lives of patients. The foundation of our conviction in leronlimab rests on both preclinical and clinical evidence. From laboratory insights to encourag...

September 30, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpo...

CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclona...

September 25, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Present at the AACR Special Conference: Mechanisms of Cance...

CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced it has been selected for a poster and an oral presentation at the upcoming A...

September 16, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annua...

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT. CytoDyn CF...

September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch